These findings suggest a potential contribution of serum concentrations of IGF-II to the development or prognosis of heart failure, and the measurement of this biomarker could help anticipate the risk of heart failure in subjects without cardiovascular diseases and cancer; however, further investigations are needed to confirm these associations. The gene discussed is IGF2; the disease is heart failure.